Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 12—December 2024
Dispatch

Human and Canine Blastomycosis Cases Associated with Riverside Neighborhood, Wisconsin, USA, December 2021–March 20221

Hannah E. Segaloff, Karen Wu, Samantha L. Williams, Summer Shaw, Shanna Miko, Lindsay A. Parnell, Andrew S. Hanzlicek, Kendra M. Carlson, Mark Lindsley, Ryan P. Westergaard, Mitsuru Toda2, and Suzanne N. Gibbons-Burgener2Comments to Author 
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (H.E. Segaloff, K. Wu, S.L. Williams, S. Miko, L.A. Parnell, M. Lindsley, M. Toda); Wisconsin Department of Health Services, Madison, Wisconsin, USA (H.E Segaloff, S. Shaw, R.P. Westergaard, S.N. Gibbons-Burgener); MiraVista Diagnostics, Indianapolis, Indiana, USA (A. Hanzlicek, K.M. Carlson)

Main Article

Table 1

Characteristics of 60 enrolled households during investigation of human and canine blastomycosis cases associated with riverside neighborhood, Wisconsin, USA, December 2021–March 2022*

Characteristic Values
No. humans in household
 2 (1–7) [2.0–3.0]
No. humans tested for antibodies in household†
 2 (0–4) [0.8–2.0]
No. humans with antibodies detected in household
 1 (0–3) [0–1.0]
No. dogs in household
 1 (0–4) [0–1.3]
No. dogs tested for antibodies in household‡
 1 (0–4) [0–1.0]
No. dogs with antibodies detected in household
 0 (0–2) [0]
Length of time living in neighborhood
 4.9 y (1 mo–56.5 y) [3.2 y–15.5 y]
Distance of house from construction, m
 144 (0–814.8) [92.7–219.4]
Distance of house from river, m
 341.7 (1.7–791.0) [231.1–463.2]
No. (%) households in neighborhood
Neighborhood 1 20 (33.3)
Neighborhood 2 29 (48.3)
Neighborhood 3
 11 (18.3)
No. (%) households with a clinically diagnosed case
Human case 5 (8.3)
Canine case 6 (10.0)
Both human and canine cases
 0 (0.0)
No. (%) households with any antibodies detected, n = 46 34 (73.9)
Humans with detected antibodies† 31 (67.4)
Canines with detected antibodies 7 (15.2)
Both humans and canines with detected antibodies‡
 4 (6.7)
No. (%) household members (human or canine) with antibodies detected, n = 46
0 12 (26.1)
1 22 (47.8)
2 7 (15.2)
3 4 (8.7)
4
 1 (2.2)
No. (%) households with a clinically diagnosed case, n = 11
Neighborhood 1, n = 20 2 (10.0)
Neighborhood 2, n = 29 8 (27.6)
Neighborhood 3, n = 11
 1 (9.1)
No. (%) households that participated in the serosurvey, n = 46
Neighborhood 1, n = 20 15 (75.0)
Neighborhood 2, n = 29 24 (82.8)
Neighborhood 3, n = 11
 7 (63.6)
No. (%) households with antibodies detected, n = 46
Neighborhood 1, n = 15 11 (73.3)
Neighborhood 2, n = 24 18 (75.0)
Neighborhood 3, n = 7 5 (71.4)

*Values are median (range) [IQR] except as indicated. IQR, interquartile range. †For humans, antibodies were considered detected in those returning a positive or intermediate result. ‡Antibody testing was completed by MiraVista Diagnostics for Blastomyces human and canine enzyme immunoassay.

Main Article

1The results of this investigation were presented at the Council for State and Territorial Annual Conference, June 25–29, 2023; Salt Lake City, Utah, USA.

2These senior authors contributed equally to this article.

Page created: October 25, 2024
Page updated: November 20, 2024
Page reviewed: November 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external